Skip to content
DataLookout
Menu

NCT04630730

Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 19 versions: 16 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 25 words
    • Primary completion date changed from estimate of Jun 2026 to Apr 26, 2026
    • Secondary endpoints: details revised at 10 of 10 entries
    • Publications: details revised at 1 of 1 entry
  2. Minor Site details revised at 1 of 10 sitesv18
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 10 of 10 sites
    v17
  4. Notable Enrollment target: 5 to 46v15
  5. Notable Trial status: Active, Not Recruiting to Recruiting
    • Site details revised at 10 of 10 sites
    v13
Show 10 earlier versionsHide 10 earlier versions
  1. Notable Trial status: Suspended to Active, Not Recruiting
    • Eligibility criteria expanded, about 21 words
    • Enrollment target: estimated 46 to confirmed 5
    v12
  2. Stopped Trial status: Active, Not Recruiting to Suspended Sponsor's reason: temporarily suspended for accrual due to "out of specification" notification for IMP batch.v11
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 10 of 10 sites
    v10
  4. Minor Site contacts updated at 1 of 10 sitesv9
  5. Minor Study sites: 9 to 10v8
  6. Minor Start date changed from estimate of May 2022 to Jun 24, 2022v7
  7. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jul 2022 to May 2022
    • Site details revised at 9 of 9 sites
    v5
  8. Notable Start date: Dec 2021 to Jul 2022v4
  9. Notable Primary completion date: Sep 2025 to Jun 2026v3 Show 6 more changesShow less
    • Start date: Jul 2021 to Dec 2021
    • Eligibility criteria shortened, about 2 words
    • Enrollment target: 62 to 46
    • Study sites: 6 to 9
    • Study completion date: Sep 2029 to Jun 2030
    • Secondary endpoints: details revised at 1 of 10 entries
  10. Notable Primary completion date: Feb 2025 to Sep 2025
    • Start date: Feb 2021 to Jul 2021
    v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Pathological complete remission (pCR)
Timeframe: At the date of tumor assessment after surgery, estimated at approximately 20 to 24 weeks after treatment start

Secondary (10)

Event-free survival (EFS)
Recurrence-free survival (RFS) after R0 resection
Overall survival (OS)
Quality of resection: Complete resection
Quality of resection: Completeness of the lymphadenectomy and surgery
Show 5 moreShow less
Quality of resection: Postoperative complications
Pathological response (PaR) rate
Pattern of recurrence
Treatment feasibility
Adverse events

Arms and interventions

Recombinant intravesical BCGExperimental

The Intravesical recombinant BCG (Bacillus Calmette-Guérin - VPM1002BC) is used as an immuno-stimulating agent. The patient will receive 3 weekly BCG instillations as induction treatment. 4 cycles of atezolizumab, a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1 inhibitor) will be administered in combination with the standard neoadjuvant chemotherapy cisplatin/gemcitabine. After surgery atezolizumab will be administered in the adjuvant setting for 13 cycles.

Drugs: Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC), Atezolizumab, Cisplatin, Gemcitabine

Sites

10 sites in 1 country